Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M003504200 on August 1, 2000

J. Biol. Chem., Vol. 275, Issue 42, 32775-32782, October 20, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/42/32775    most recent
M003504200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanioka, T.
Right arrow Articles by Kudo, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanioka, T.
Right arrow Articles by Kudo, I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Identification of Cytosolic Prostaglandin E2 Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E2 Biosynthesis*

Toshihiro Tanioka, Yoshihito Nakatani, Natsuki Semmyo, Makoto Murakami, and Ichiro KudoDagger

From the Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan

Received for publication, April 24, 2000, and in revised form, July 31, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here we report the molecular identification of cytosolic glutathione (GSH)-dependent prostaglandin (PG) E2 synthase (cPGES), a terminal enzyme of the cyclooxygenase (COX)-1-mediated PGE2 biosynthetic pathway. GSH-dependent PGES activity in the cytosol of rat brains, but not of other tissues, increased 3-fold after lipopolysaccharide (LPS) challenge. Peptide microsequencing of purified enzyme revealed that it was identical to p23, which is reportedly the weakly bound component of the steroid hormone receptor/hsp90 complex. Recombinant p23 expressed in Escherichia coli and 293 cells exhibited all the features of PGES activity detected in rat brain cytosol. A tyrosine residue near the N terminus (Tyr9), which is known to be critical for the activity of cytosolic GSH S-transferases, was essential for PGES activity. The expression of cPGES/p23 was constitutive and was unaltered by proinflammatory stimuli in various cells and tissues, except that it was increased significantly in rat brain after LPS treatment. cPGES/p23 was functionally linked with COX-1 in marked preference to COX-2 to produce PGE2 from exogenous and endogenous arachidonic acid, the latter being supplied by cytosolic phospholipase A2 in the immediate response. Thus, functional coupling between COX-1 and cPGES/p23 may contribute to production of the PGE2 that plays a role in maintenance of tissue homeostasis.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Biosynthesis of prostaglandin (PG)1 E2, the most common prostanoid with potent bioactivities, is regulated by three sequential steps of the cyclooxygenase (COX) pathway. Phospholipase A2 (PLA2) initiates this pathway by releasing arachidonic acid (AA) from membrane glycerophospholipids. Of more than 10 members of the PLA2 family characterized to date, cytosolic PLA2 (cPLA2) and several secretory PLA2s are involved in supplying AA to either of the two COX isozymes, COX-1 and COX-2, depending upon the phases of cell activation (1-3). The constitutive COX-1 is mainly utilized in immediate PGE2 biosynthesis, which occurs within several minutes after stimulation with Ca2+ mobilizers, whereas the inducible COX-2 mediates the delayed PGE2 biosynthesis, which lasts for several hours following proinflammatory stimuli. Although COX-1 and COX-2 have been reported to exhibit subtle differences in AA requirements in that COX-2 is favored over COX-1 at low AA concentrations (3-5) and subcellular localizations (6), their functional segregation in the PGE2 biosynthetic response cannot be fully explained only by these aspects.

The activity of PGES, which catalyzes conversion of COX-derived PGH2 to PGE2, has been detected in both cytosolic and microsomal fractions of various cells, and in most, if not all, cases it requires glutathione (GSH) for optimal activity (7-9). Although several groups have attempted to purify this critical enzyme to near homogeneity for the last 20 years (7-9), such trials have been unsuccessful. The PGES enzyme purified from human brain cytosol was identified as a GSH S-transferase (GST), which converts PGH2 to PGE2, PGD2, and PGF2alpha nonspecifically (9). GSH-independent PGES with a molecular mass of 31 kDa was recently purified from bovine heart (10). Interestingly, PGES activity has been shown to be strongly induced by proinflammatory stimuli in macrophages (11, 12). More recently, microsomal GST1-like 1 (MGST1-L1), a member of the MAPEG (membrane-associated proteins involved in eicosanoid and glutathione metabolism) superfamily, has been shown to exhibit significant PGES activity (13, 14).

In this study, we report the molecular identification of cytosolic PGES (cPGES), a GSH-requiring enzyme that is expressed ubiquitously in a wide variety of cells and tissues. Importantly, this enzyme is capable of converting COX-1-, but not COX-2-, derived PGH2 to PGE2 efficiently. Our present results, together with identification of the inducible membrane-associated PGES that is preferentially coupled with COX-2 as described in the accompanying paper (15), revealed that segregated utilization of the biosynthetic enzymes in different phases of PG production also occurs at the step of terminal synthases.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Animals-- Wistar rats (7 weeks old, male) were purchased from Japan Bio-Supply center (Tokyo, Japan). Rabbits (New Zealand White, 1-kg body weight, female) were from Saitama Experimental Animal Supply (Saitama, Japan).

Cells-- Human embryonic kidney 293 cells were obtained from Japanese Cancer Resources Bank. Rat fibroblastic 3Y1 cells were donated by Dr. Y. Uehara (National Institute of Infectious Disease, Tokyo, Japan). Human cervix epithelial HeLa cells, human stomach MKN45 cells, human glial U251 cells, human fibroblastic WI38 cells, human neuroblastoma GOTO cells, Chinese hamster ovary (CHO) cells, mouse osteoblastic MC3T3-E1 cells, and mouse fibroblastic L929 cells were obtained from the RIKEN Cell Bank. GOTO, HEK293, CHO, MKN45 and L929 were cultured in RPMI 1640 medium (Nissui Pharmaceutical) containing 10% fetal calf serum (FCS; Bioserum), WI38. U251 and 3Y1 in DMEM (Nissui Pharmaceutical) containing 10% FCS, and MC3T3-E1 in alpha -minimal essential medium (Dainippon Pharmaceutical) containing 10% FCS.

Materials-- The goat anti-human COX-2 and rabbit anti-human cPLA2 antibodies were purchased from Santa Cruz. The rabbit anti-mouse COX-1 antibody was provided by Dr. W. L. Smith (Michigan State University, East Lansing, MI). cDNA probes for human COX-1, human COX-2 and mouse COX-2 were described previously (2, 16). LipofectAMINE Plus, LipofectAMINE 2000, Opti-MEM, and TRIzol reagent were obtained from Life Technologies. Bacterial LPS (Salmonella minnesota Re 595), 1-chloro-2,4-dinitrobenzene (CDNB), indomethacin, and GSH were purchased from Sigma. Ethacrynic acid, 1,2-dichloro-4-nitrobenzene, and p-nitrophenethyl bromide were from Wako. Freund's complete and incomplete adjuvants were from Difco Laboratories. AA, PGH2, rabbit anti-human COX-1 antibody, and the enzyme immunoassay kits for PGE2 were from Cayman Chemical. Oligonucleotide primers were from Amersham Pharmacia Biotech. Geneticin, hygromycin, and the mammalian expression vectors pCR3.1 and pCDNA3.1/hyg(+) were purchased from Invitrogen. A23187 was purchased from Calbiochem. Human and mouse interleukin (IL)-1beta and tumor necrosis factor (TNF) alpha  were from Genzyme. Fluorescein isothiocyanate-conjugated goat anti-rabbit IgG and horseradish peroxidase-conjugated anti-rabbit and mouse IgGs were purchased from Zymed Laboratories Inc. Other reagents were obtained from Wako Pure Chemical Industries. Computational analysis on the protein and cDNA sequences were performed using the GENETYX program (Software Development).

Assay of Enzymatic Activity of PGES-- PGES activities in cell lysates were measured by assessment of conversion of PGH2 to PGE2 as previously reported (11). The cells were scraped off from the dishes and disrupted by sonication using Branson Sonifier (10 s, three times, 1-min interval) in 400 µl of 10 mM Tris-HCl (pH 8.0). After centrifugation of the sonicates at 1,700 × g for 10 min at 4 °C, the supernatants were used as the enzyme source. An aliquot of each lysate (10 µg of protein equivalents) was incubated with 0.5 µg of PGH2 for 30 s at 24 °C in 0.1 ml of 0.1 M Tris-HCl (pH 8.0), containing 1 mM GSH and 5 µg of indomethacin. After terminating the reaction by the addition of 100 mM FeCl2, PGE2 contents in the supernatants were quantified by use of the enzyme immunoassay kit. Protein concentrations were determined by the protein assay kit (Pierce) using bovine serum albumin (BSA) as a standard.

Purification of PGES from Rat Brain Cytosol-- Brains obtained from 10 Wistar rats 48 h after intravenous injection of 150 µg/kg LPS were homogenized in 100 ml of SET buffer comprising 20 mM Tris-HCl (pH 7.4), 250 mM sucrose, 5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride by using a Potter homogenizer. After centrifugation at 100,000 × g, the supernatant was subjected to 60-80% ammonium sulfate precipitation. The precipitate obtained by centrifugation for 30 min at 10,000 × g at 4 °C was dissolved in SET buffer, dialyzed against 20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 1 µM leupeptin, and 1 µM antipain, and then applied to a DEAE-Sephacel ion-exchange column (1 × 7 cm) (Amersham Pharmacia Biotech) at a flow rate of 30 ml/h. The bound proteins were eluted with 25 mM Tris-HCl (pH 7.4) containing 1 mM EDTA and a linear gradient of 0.15-1 M NaCl. Fractions containing PGES activity were concentrated to 1 ml using Centriprep 10 (Amicon) and applied to a Superdex 200 gel filtration column (Amersham Pharmacia Biotech) equilibrated with 20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 1 mM EDTA, and 0.1 mM phenylmethylsulfonyl fluoride at a flow rate of 0.5 ml/min. A 10-µl aliquot of each fraction was taken for PGES enzyme assay.

Peptide Microsequencing-- The protein band on the first sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was visualized by Coomassie Brilliant Blue, cut out from the gel, and then digested in the second gel with 10 µg of V8 protease (Sigma). The resultant peptides were electrotransferred to a polyvinylidene difluoride membrane (Millipore), and the three major peptide fragments obtained were subjected to amino acid sequencing using an Applied Biosystems 473A protein sequencer, as described previously (17).

Isolation of cPGES/p23 cDNA-- Total RNA from HeLa cells was subjected to a reverse transcription reaction using RNA PCR kit (avian myeloblastosis virus) (Takara Biomedicals). cDNA thus obtained was subjected to PCR using the human p23 (18) primers 5'-ATGCAGCCTGCTTCTGCA-3' and 5'-TTACTCCAGATCTGGCAT-3' (94 °C for 30 s, 50 °C for 30 s, and 72 °C for 30 s, for 25 cycles). An amplified product of the expected size was subcloned into pCR3.1 (Invitrogen) and transfected into E. coli Top10F' (Invitrogen). The plasmid was isolated and sequenced using a thermo sequenase fluorescent-labelled primer cycle sequencing kit with 7-deaza-dGTP (Amersham Pharmacia Biotech) and an autofluorometric DNA sequencer DSQ-1000L (Shimadzu).

Preparation of Recombinant cPGES/p23-- Human p23 cDNA (18) was subcloned into pET21c (Novagen) and transformed into E. coli BL21 (DE3) (Stratagene). The cells were cultured until they reached the late lag phase, and 0.3 mM isopropyl-1-thio-beta -D-galactopyranoside was added to induce (His)6-tagged protein. Bacterial cell pellets were lysed in 20 mM Tris-HCl (pH 8) containing 0.5 M NaCl, 10% glycerol, and 6 M guanidine HCl by stirring for 30 min at room temperature. After centrifugation at 15,000 × g for 30 min at 4 °C, the resulting supernatants were applied to a nickel-nitrilotriacetic acid-agarose column (Qiagen) preequilibrated with 100 mM NiSO4 at a flow rate of 10 ml/h. After washing, the bound protein was eluted with the same buffer containing 20-60 mM imidazole in a stepwise manner.

Site-directed Mutagenesis-- To obtain cPGES/p23 Y9N mutant, mismatched primer PCR was carried out using ex Taq polymerase with cPGES/p23 cDNA as a template and the primers 5'-ATG CAG CCT GCT TCT GCA AAG TGG AAC G-3' (the mutated base is underlined) and 5'-TTA CTC CAG ATC TGG CAT-3'. PCR conditions were 94 °C for 30 s, 50 °C for 30 s, and 72 °C for 30 s, for 25 cycles. The fragment obtained was subcloned into pCR3.1 and sequenced.

Expression of cPGES/p23 in 293 Cells-- The cDNA flanking the entire open reading frame of human cPGES/p23 was subcloned into the mammalian expression vector pCDNA3.1/hyg(+) and transfected into 293 cells stably expressing human COX-1 or COX-2, which we had previously established (2), using LipofectAMINE Plus according to the manufacturer's instruction. Briefly, 1 µg of each plasmid was mixed with 4 µl of LipofectAMINE and 6 µl of Plus reagent in 200 µl of Opti-MEM, left for 15 min, and then added to cells that had attained 70% confluence in six-well plates (Iwaki Glass) in 1 ml of Opti-MEM. After incubation for 4 h, 2 ml of fresh culture medium was added. After 18 h, the medium was replaced with 2 ml of fresh medium, and the culture was continued for 3 days. In order to establish stable transfectants, cells transfected with each cDNA were cloned by limiting dilution in 96-well plates (Iwaki Glass) in culture medium supplemented with 50 µg/ml hygromycin. After 3-4 weeks of culture, single colonies were picked up and expanded. Expression of cPGES/p23 and each COX was assessed by RNA blotting and immunoblotting, as described below.

Cell Activation-- All procedures were described in our previous reports (1-3). Briefly, 293 cells (5 × 104/ml) were seeded into each well of 24- or 48-well plates in 1 and 0.5 ml of culture medium, respectively. After culture for 4 days, the cells were washed once with culture medium and then incubated with 250 µl (24-well plate) or 100 µl (48-well plate) of various concentrations of AA or 10 µM A23187 in medium containing 1% FCS for 30 min or 1 ng/ml IL-1beta in medium containing 10% FCS for 4 h. The supernatants were subjected to the PGE2 enzyme immunoassay. Activation of other cell lines was carried out in a similar way.

Preparation of Antibody against cPGES/p23-- The (His)6-tagged cPGES/p23 (500 µg) in 500 µl of phosphate-buffered saline was mixed with an equal volume of Freund's complete adjuvant and injected into rabbits. Immunization was repeated every 3 weeks with the same amounts of the antigen mixed with an equal volume of Freund's incomplete adjuvant. Serum titers were checked by the enzyme-linked immunosorbent assay (see below), followed by Western blotting (see below) using the purified recombinant (His)6-tagged cPGES/p23 and the lysate of HeLa cells.

In the enzyme-linked immunosorbent assay, 1 µg/ml recombinant (His)6-tagged cPGES/p23 was coated on Immulon 2 plates (Dynatech Laboratories) (50 µl/well) overnight at 4 °C. Subsequent procedures were performed at room temperature. After washing with 10 mM Tris-HCl (pH 7.4) containing 0.05% Tween 20 and 150 mM NaCl (TBS-T), the plates were incubated for 1 h with 5% skim milk in PBS. After six washes with TBS-T, serial dilutions of rabbit antisera were added to the plates (50 µl/well) and incubated for 1 h. After 6 washes with TBS-T, the plates were incubated with horseradish peroxidase-conjugated anti-rabbit IgG (50 µl/well) at a 1:1,000 dilution for 1 h. After 6 washes, the plates were incubated with o-phenylenediamine. After terminating the reaction by adding 4 N H2SO4, absorbance at 490 nm was measured.

RNA Blotting-- Approximately equal amounts (~10 µg) of the total RNAs obtained from the transfected cells were applied to separate lanes of 1.2% (w/v) formaldehyde-agarose gels, electrophoresed, and transferred to Immobilon-N membranes (Millipore). The resulting blots were then probed with the respective cDNA probes that had been labeled with [32P]dCTP (Amersham Pharmacia Biotech) by random priming (Takara Biomedicals). All hybridizations were carried out as described previously (19).

SDS-PAGE/Immunoblotting-- Cell lysates (105 cell equivalents) or culture supernatants were subjected to SDS-PAGE using 15% (w/v) gels for cPGES/p23 and 10% gels for COXs under reducing conditions. The separated proteins were electroblotted onto nitrocellulose membranes (Schleicher & Schuell) using a semidry blotter (MilliBlot-SDE system; Millipore). The membranes were probed with the respective antibodies and visualized using the ECL Western blot system (PerkinElmer Life Sciences), as described previously (19).

Immunofluorescent Confocal Microscopic Analysis-- Cells were seeded onto cover glasses (Matsunami Glass) at 1 × 105 cells/ml and cultured for 1 day. After removing the supernatants, the cells were fixed with 10% (v/v) formalin in PBS for 30 min at 4 °C. The cells were then treated 0.2% (v/v) Triton X-100 for 2 min, washed six times, and incubated for 1 h with 3% (w/v) BSA in PBS (PBS-BSA). After three washes, the cells were incubated with rabbit anti-cPGES/p23 antibody (1:200 dilution) in PBS-BSA for 2 h, washed three times, and then incubated with fluorescein isothiocyanate-conjugated anti-rabbit IgG (1:100 dilution) in PBS-BSA for 1 h. After six washes, the coverslips were mounted on glass slides using Perma Fluor (Japan Tanner) and examined using a Fluoview laser fluorescence microscope (Olympus).

Transfection of Antisense cPGES/p23 cDNA into 3Y1 Cells-- Approximately 4 µg of cPGES/p23 cDNA subcloned into pCR3.1 in an inverse direction were incubated with 5 µl of LipofectAMINE 2000 reagent in 200 µl of Opti-MEM for 15 min at room temperature and then added to cells that had attained 60-80% confluence in six-well plates and been supplemented with 800 µl of Opti-MEM. After incubation for 6 h at 37 °C, 1 ml of DMEM supplemented with 2% FCS was added, and the culture was continued for another day. Then the cells were trypsinized, seeded into 24-well plates, and cultured for 2 days. After washing once with DMEM, the cells were stimulated for 30 min with 10 µM A23187 in DMEM or for 12 h with 1 ng/ml mouse IL-1beta and mouse TNFalpha in DMEM containing 2% FCS. The supernatants were taken for PGE2 enzyme immunoassay, and the cells were subjected to PGES enzyme assay and immunoblotting.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Detection of PGES Activity in the Cytosol of Rat Tissues-- In an effort to identify PGES isoforms, we measured PGES activity, which converts PGH2 to PGE2, in the cytosol of various rat tissues before and 48 h after injection of LPS. All tissues examined contained significant PGES activity that was not affected by LPS, except that the activity in brain increased up to 3-fold 48 h after LPS challenge (Fig. 1A). This activity was stimulated markedly by GSH and was inhibited by CDNB, a substrate for several GST enzymes (20) (Fig. 1B).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Detection of PGES activity in rat tissues. A, cytosolic PGES activity in the cytosol fraction of various rat tissues with or without treatment with LPS for 48 h was measured in the presence of 1 mM GSH. B, PGES activity in the cytosol fraction of LPS-treated rats was assessed in the presence or absence of 1 mM GSH and 1 mM CDNB.

Purification of PGES-- LPS-sensitive PGES activity in rat brain cytosol fraction was recovered in the 60-80% ammonium sulfate precipitated fraction (Fig. 2A). When this fraction was dialyzed and then applied to DEAE-Sephacel ion-exchange column chromatography, a single major peak of PGES activity was eluted with 0.5 M NaCl (Fig. 2B). The activity obtained from LPS-treated rat brains was significantly higher than that obtained from untreated animals. When the fractions containing PGES activity were then applied to Superdex 200 gel filtration, there were three major peaks that exhibited significant PGES activity, among which only the activity eluted in fractions corresponding to a molecular mass of ~50 kDa (around fraction 78) showed severalfold higher activity than that in replicate fractions purified from rats not treated with LPS (Fig. 2C). On SDS-PAGE, this activity comigrated with a major protein with an apparent molecular mass of 26 kDa, which was detected more faintly in the untreated group. The specific activity of the peak fraction purified from LPS-treated rat brains after gel filtration was estimated to be approximately 5 µmol/min/mg of protein. This activity showed dependence on GSH and was inhibited by CDNB (data not shown). There was no detectable GST activity toward several cytosolic GST substrates, such as CDNB, 1,2-dichloro-4-nitrobenzene, p-nitrophenethyl bromide, and ethacrynic acid (data not shown). On the other hand, the other two higher molecular weight PGES peaks, which were eluted in fractions 53 and 69 in both LPS-treated and -untreated groups (Fig. 2C), were fairly insensitive to CDNB (data not shown). These results suggest that there are several proteins that exhibit PGES activity with different enzymatic properties in the cytosol.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 2.   Purification of PGES from rat brain cytosol fractions. A, ammonium sulfate precipitation. PGES activity in 0-60% and 60-80% ammonium sulfate-precipitated fractions obtained from rat brains with or without treatment with LPS for 48 h was measured in the presence of 1 mM GSH. B, fractions precipitated by 60-80% ammonium sulfate were dialyzed and subjected to DEAE-Sephacel ion-exchange column chromatography. Bound proteins were eluted with a linear gradient of NaCl from 0.15 to 1 M. A 10-µl portion of each fraction was taken for PGES assay. C, fractions containing PGES activity in panel B were applied to Superdex 200 gel filtration, and a 10-µl portion of each fraction was taken for PGES assay. Fractions 71-83 were subjected to SDS-PAGE, and proteins were visualized by silver staining. Detailed chromatographic procedures are described under "Experimental Procedures."

Molecular Indentification of Cytosolic PGES-- Peptide mapping of the 26-kDa protein revealed that the partial amino acid sequences (MDPASAKWYDRRDYVFIEFC, KSKLCFSCLG, and IDLFHCIDPN) were identical to those of the corresponding portions (1-20, 33-42, and 53-62, respectively) of human p23, a cytosolic protein that is the weakly bound component of the steroid hormone receptor/hsp90 complex with a putative chaperone function (18, 21). We therefore isolated the full-length human p23 cDNA from HeLa cells and expressed it in E. coli as a C-terminally (His)6-tagged protein. The recombinant protein purified by nickel-chelating column had significant PGES activity in the presence of GSH and was inhibited by CDNB (Fig. 3A), whereas formation of other PGs was negligible (data not shown). The Km and Vmax values of the recombinant protein for PGH2 were estimated to be 14 µM and 190 nmol/min/mg of protein, respectively, in our in vitro assay system. GST activity was undetected when CDNB, 1,2-dichloro-4-nitrobenzene, p-nitrophenethyl bromide, and ethacrynic acid were used as substrates (data not shown). Furthermore, PGES activity in lysate of p23-transfected HEK293 cells was stimulated markedly by GSH as compared with mock-transfected cells, and was inhibited by CDNB (Fig. 3B). Thus, we conclude that p23 indeed possesses PGES activity, and therefore designate it cPGES/p23 (c stands for cytosolic) hereafter.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Biochemical analyses of cPGES/p23. A, the PGES activity of the bacteria-derived recombinant p23 protein was measured in the presence or absence of 1 mM GSH and 1 mM CDNB. B, the PGES activity in lysates of HEK293 cells 3 days after transfection of human cPGES/p23 cDNA/pCR3.1 or the control vector was measured in the presence or absence of 1 mM GSH and 1 mM CDNB.

Although the homology between cPGES/p23 and other known cytosolic GSTs (including hematopoietic PGD2 synthase (Ref. 22)) is low (~20%), near the N terminus cPGES/p23 has a tyrosine residue (Tyr9) that is conserved in several other cytosolic GSTs as well as hematopoietic PGD2 synthase (Fig. 4A). The tyrosine residue in this position serves as a GSH acceptor, thereby being essential for catalytic activity (20, 22). As shown in Fig. 4B, the cPGES/p23 mutant in which Tyr9 was replaced by Asn exhibited virtually no PGES activity when transfected into HEK293 cells.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Tyr9 is essential for cPGES/p23 activity. A, alignment of the N-terminal amino acid sequences of several human cytosolic GSTs, hematopoietic PGD2 synthase (hPGDS), and cPGES/p23. A tyrosine residue essential for the catalytic activity is boxed. B, cPGES/p23 (wild-type (WT) and Y9N mutant) cDNA subcloned into pCR3.1 and the empty vector were transfected into HEK293 cells, and PGES activity in cell lysates 3 days after transfection was measured in the presence of 1 mM GSH. Expression of recombinant protein was confirmed by immunoblotting using anti-cPGES/p23 antibody (top panel).

Expression of cPGES/p23 in Various Cells and Tissues-- RNA blot analysis showed that cPGES/p23 was most abundantly expressed in the testis, and was also expressed in various tissues of the rat (Fig. 5A). In most tissues, expression was unchanged following LPS treatment. Exceptionally, cPGES/p23 mRNA expression in brain was increased approximately 3-fold after treatment with LPS (Fig. 5A), a result consistent with increased PGES activity in brain cytosol fraction (Fig. 1A). Immunoblotting using anti-cPGES/p23 antibody confirmed the increased expression of cPGES/p23 protein in LPS-treated rat brain cytosol fraction (Fig. 5B). cPGES/p23 mRNA was detected in the kidney only faintly (Fig. 5A), whereas PGES activity in the kidney cytosol was higher than that in other tissues (Fig. 1A), suggesting that there are other types of PGES in this tissue. cPGES/p23 was expressed constitutively and was not altered significantly by stimulation with cytokines (TNFalpha and IL-1beta ) in all cell lines examined (Fig. 5C). Confocal microscopic analysis using an anti-cPGES antibody revealed that cPGES is located in the cytosol of these cells (Fig. 6).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   Tissue and cellular distribution of cPGES/p23. A, expression of cPGES/p23 mRNA in various rat tissues. Total RNA (10 µg) obtained from various tissues of rat before and 48 h after injection of LPS was subjected to RNA blotting using cPGES/p23 cDNA as a probe. B, increased expression of cPGES/p23 protein in LPS-treated rat brain. The 100,000 × g supernatants and pellets of rat brain homogenates were subjected to immunoblotting using the anti-cPGES/p23 antibody. C, expression of cPGES/p23 mRNA in various cell lines before and 24 h after stimulation with 1 ng/ml IL-1beta and 100 units/ml TNFalpha .


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 6.   Subcellular distribution of cPGES/p23. Cells were fixed with folmalin, permeabilized, and then incubated sequentially with rabbit anti-cPGES/p23 antibody and fluorescein isothiocyanate-conjugated anti-rabbit IgG. The cells were mounted, and their fluorescence was visualized using a laser scanning confocal microscope.

Functional Coupling between cPGES/p23 and COXs-- To assess whether cPGES/p23 plays a role in PGE2 production by live cells, human cPGES/p23 cDNA was cotransfected with either COX-1 or COX-2 into HEK293 cells to establish their stable transfectants (Fig. 7A). Whereas cells expressing COX-1 alone produced significantly more PGE2 than control cells, particularly when a high concentration (10 µM) of AA was added, as reported previously (2), cotransfection of COX-1 and cPGES/p23 led to a marked increase in PGE2 that was detectable at lower AA concentrations (Fig. 7B, left). Approximately 10-fold increase in PGE2 formation by COX-1-cPGES/p23 cotransfectants relative to that by COX-1 single transfectants at all AA doses tested (Fig. 7B, left) appeared to correlate with the expression levels of overexpressed versus endogenous cPGES/p23 (Fig. 7A). On the other hand, PGE2 generation by COX-2-expressing cells was increased minimally even after cPGES cotransfection (Fig. 7B, right).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7.   Functional coupling between COXs and cPGES/p23 in HEK293 transfectants. A, the expression levels of COX-1, COX-2, and cPGES/p23 in HEK293 cells stably transfected with their cDNAs, alone or in combination, were assessed by RNA blotting and immunoblotting. B, conversion of exogenous AA to PGE2. Cells transfected with both cPGES and either COX (filled circles), cells transfected with either COX alone (open circles), and control cells (open squares) were incubated for 30 min with the indicated concentrations of AA, and PGE2 released into the supernatants was quantified. C, production of PGE2 from endogenous AA. HEK293 cells stably transfected with cPLA2, COX-1, COX-2, and cPGES/p23, alone or in combination, were stimulated for 30 min with 10 µM A23187 (left) or for 4 h with 1 ng/ml human IL-1beta (right). Expression of cPLA2 as assessed by RNA blotting is shown in the inset of the right panel.

To assess the metabolism of endogenous AA, these transfectants were stimulated for 30 min with A23187 (immediate response) or for 4 h with IL-1 (delayed response). Although A23187-induced PGE2 generation was not increased significantly in cells coexpressing COX-1 and cPGES/p23, further introduction of cPLA2, which caused the burst release of AA (1), led to a dramatic increase in the production of PGE2 (Fig. 7C, left). A23187-induced PGE2 generation by cPLA2-COX-1 cotransfectants was about one tenth that by cPLA2-COX-1-cPGES/p23 cotransfectants (Fig. 7C, left), suggesting that the former occurs through the pathway involving overexpressed cPLA2-COX-1 and endogenous cPGES/p23. In contrast, PGE2 generation by A23187-stimulated COX-2-expressing cells was increased only modestly when cPLA2 and cPGES/p23 were coexpressed (Fig. 7C, left). Moreover, cPGES/p23 did not promote delayed PGE2 biosynthesis induced by IL-1 even when combined with cPLA2 and either of the two COX isozymes (Fig. 7C, right). Collectively, these results suggest that cPGES/p23 mediates COX-1-dependent immediate PGE2 synthesis.

To ensure that the preferential coupling between COX-1 and cPGES/p23 was not a peculiarity of the 293 transfectants, we next examined the functional coupling between the endogenous enzymes. When antisense cDNA for cPGES/p23 was transiently transfected into rat fibroblastic 3Y1 cells, in which COX-1-dependent immediate and COX-2-dependent delayed PGE2-biosynthetic responses occur in response to A23187 and IL-1/TNF, respectively (23), the expression of cPGES/p23, but not COX-1, protein was decreased by half (Fig. 8A, inset), with a concomitant reduction of PGES activity in cell homogenates (Fig. 8A). Importantly, A23187-elicited immediate, but not IL-1/TNF-induced delayed, PGE2 generation was suppressed by half in cells transfected with the cPGES/p23 antisense cDNA (Fig. 8B).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of cPGES/p23 antisense cDNA on PGE2 generation in rat fibroblastic 3Y1 cells. A, the PGES activity in the cytosol of 3Y1 cells 3 days after transfection with cPGES/p23 antisense cDNA/pCR3.1 or empty vector was assessed. The expression of cPGES/p23 and COX-1 proteins, as assessed by immunoblotting, is shown in the inset. B, the cells were stimulated for 30 min with 10 µM A23187 and for 12 h with 1 ng/ml mouse IL-1beta plus 100 units/ml mouse TNFalpha to assess the immediate and delayed phases of PGE2 generation, respectively. PGE2 generation without stimuli was <1 ng/well in both phases (data not shown).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present study, we have identified for the first time a cytosolic form of PGES, which is fully functional in mammalian cells. It is a GSH-requiring enzyme expressed in a wide variety of cells and tissues, and is identical to p23, a putative chaperone molecule that binds to the ATP-dependent conformation of hsp90 and stabilizes preformed steroid hormone receptor/hsp90 heterocomplexes (18, 21, 24). p23 was initially suggested to be required for refolding of the receptor to the steroid binding conformation (25). However, subsequent studies demonstrated that p23 is not essential for the folding change of the steroid hormone receptor (26) and that deletion of the p23 gene in yeast does not ablate glucocorticoid receptor action (27). It has recently been proposed that p23 might play some role(s) at later steps in intracellular receptor-mediated signal transduction, perhaps including receptor recycling and reversal of the response (28), and the assembly of active telomerase complex (29). However, the precise cellular functions of p23 have remained obscure.

Several lines of evidence suggest that p23 is a functional GSH-dependent PGES. First, recombinant expression of p23 in both bacteria and mammalian cells reproduced PGES activity indistinguishable from that of the enzyme purified from rat brain in terms of GSH requirement and CDNB sensitivity (Figs. 1-3). Unlike typical cytosolic GSTs (20), the GST activity of recombinant p23 toward several cytosolic GST substrates was negligible. These properties are similar to those of hematopoietic PGD2 synthase, another GSH-requiring terminal prostanoid synthase belonging to the sigma  class of GSTs (22). Second, as in the case of various cytosolic GSTs and hematopoietic PGD2 synthase (20, 22), a tyrosine residue near the N terminus of p23 is essential for enzyme activity (Fig. 4). Third, moderate changes in expression of p23 mRNA and protein paralleled that in PGES activity in rat brain cytosol following LPS treatment (Figs. 1 and 5). Fourth, transfection of p23 into HEK293 cells dramatically increased the cells' capacity to produce PGE2, particularly when combined with COX-1 (Fig. 7). Finally, reduction of p23 expression by antisense treatment led to a concomitant decrease in A23187-induced, COX-1-dependent PGE2 generation in 3Y1 cells (Fig. 8). In contrast, p23 expression minimally affected COX-2-dependent PGE2 generation (Figs. 7 and 8). Thus, cPGES/p23 is preferentially linked with COX-1, a constitutive COX isozyme, promoting the immediate PGE2 biosynthetic response, and physiologically it may contribute to production of PGE2 required for the maintenance of tissue homeostasis.

Since cPGES/p23 was eluted at >50 kDa on gel filtration (Fig. 2C), it may form a homodimer, as do cytosolic GSTs (20), and this has been recently verified by others (30). Alternatively, it may form a heterooligomer with other cellular components. The latter possibility is in line with the notion that p23 assembles in the hsp90-directed steroid hormone receptor (18, 21, 24-28) or telomerase (29) complex. Since the other PGES peaks detected on gel filtration (Fig. 2C) were CDNB-insensitive, it is likely that they reflect the presence of multiple forms of PGES other than CDNB-sensitive cPGES/p23 in cells.

That cPGES/p23 functions as a PGE2-biosynthetic enzyme and as a putative chaperone of lipophilic steroid hormone receptors (18, 21, 24-28) implies its multifunctional role. This property is reminiscent of that of lipocalin-type PGD2 synthase, which not only plays a role in production of PGD2 in the central nervous system (31) but also binds to several lipophilic ligands, such as biliverdin, bilirubin, and thyroid hormones (32), and functions as a retinoid transporter (33). PGF synthase is a member of the aldo-keto reductase superfamily, the enzymes belonging to which exhibit reductase activities toward various carbonyl compounds in addition to PGH2 (34, 35). Whether cPGES/p23 displays enzymatic activity toward lipophilic substances other than PGH2 remains to be elucidated.

The Km value of the recombinant cPGES/p23 purified from E. coli was calculated to be 14 µM, which was comparable to the Km of other cytosolic terminal PG synthases, including lung-type (10 µM) and liver-type (25 µM) PGFSs (35) and hematopoietic PGD2 synthase (500 µM) (36), and the Vmax value (190 nmol/min/mg) was also similar to that of PGFSs (200-400 nmol/min/mg) (35), although the in vitro assay conditions for each enzyme differ. It should be noted that the activity of bacterially expressed cPGES/p23 appeared to be approximately 1 order lower than that of the enzyme purified from rat brain or the recombinant enzyme expressed in HEK293 cells. This may be a reflection of the presence of certain interacting cofactor(s) in samples prepared from mammalian sources. It is also possible that in mammalian cells cPGES/p23 undergoes posttranslational modifications such as phosphorylation, which may lead to enzymatic activation. In support of this idea, cPGES/p23 has multiple putative phosphorylation sites (18). Alternatively, a weaker activity of the bacterially expressed enzyme may be caused by aberrant folding of the recombinant protein in bacteria, by the linkage of the artificial tag to the C terminus, or by the presence of substance(s), which interferes with measurement of the activity, in samples.

The reason why cPGES/p23 prefers COX-1 to COX-2 is currently unknown. cPGES/p23 is predominantly present in the cytosol (Fig. 6) distal from the perinuclear COXs (37, 38), and its cytosolic location was not altered by A23187 stimulation of cells (data not shown). Since COX-1, rather than COX-2, spreads into the cytosol along the endoplasmic reticular membrane (39, 40), albeit not in all cases (41), this subtle difference in subcellular localization of the two COXs might account, at least in part, for the COX-1 selectivity of cPGES/p23. Another possibility is the presence of certain cofactor(s) that may assist the functional coupling between COX-1 and cPGES/p23. Indeed, 5-lipoxygenase-activating protein acts as an essential cofactor that links cPLA2 and 5-lipoxygenase by presenting AA released by the former to the latter in the leukotriene-biosynthetic pathway (42). As p23 reportedly assembles in a steroid hormone/hsp90 complex, which translocates from the cytosol into the nucleus in a ligand-dependent manner, steroid hormones may modulate the subcellular locations of cPGES/p23 and thereby alter its PGE2-biosynthetic capacity in cells.

PGE2 is also produced in the delayed phase of the inflammatory responses in vitro and in vivo, during which COX-2, but not COX-1, plays a dominant role (1-3, 5, 11, 19, 23, 43). Considering that cPGES/p23 exerts its function only in COX-1-dependent immediate PGE2 biosynthesis, another PGES enzyme(s) that is selectively coupled with COX-2 in the delayed response must exist in cells. In this context, MGST1-L1, a member of the MAPEG superfamily (13, 14), is a strong candidate for the terminal enzyme involved in this process. In the accompanying paper (15), we provide evidence that MGST1-L1, a GSH-requiring, inducible perinuclear PGES, promotes the COX-2-dependent PGE2-biosynthetic pathway.

    FOOTNOTES

* This work was supported by grants-in-aid for scientific research from the Ministry of Education, Science and Culture of Japan and special coordination funds for promoting science and technology from the Science and Technology Agency.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 81-3-3784-8196; Fax: 81-3-3784-8245; E-mail: kudo@pharm.showa-u.ac.jp.

Published, JBC Papers in Press, August 1, 2000, DOI 10.1074/jbc.M003504200

    ABBREVIATIONS

The abbreviations used are: PG, prostaglandin; cPGES, cytosolic prostaglandin E2 synthase; PGES, prostaglandin E2 synthase; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; LPS, lipopolysaccharide; GSH, glutathione; GST, glutathione S-transferase; MGST1-L1, microsomal GST1-like 1; AA, arachidonic acid; CDNB, 1-chloro-2,4-dinitrobenzene; IL, interleukin; TNF, tumor necrosis factor; FCS, fetal calf serum; BSA, bovine serum albumin; PAGE, polyacrylamide gel electrophoresis; CHO, Chinese hamster ovary; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; PLA2, phospholipase A2.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Murakami, M., Shimbara, S., Kambe, T., Kuwata, H., Winstead, M. V., Tischfield, J. A., and Kudo, I. (1998) J. Biol. Chem. 273, 14411-14423
2. Murakami, M., Kambe, T., Shimbara, S., and Kudo, I. (1999) J. Biol. Chem. 274, 3103-3115
3. Murakami, M., Kambe, T., Shimbara, S., Higashino, K., Hanasaki, K., Arita, H., Horiguchi, M., Arita, M., Arai, H., Inoue, K., and Kudo, I. (1999) J. Biol. Chem. 274, 31435-31444
4. Kulmacz, R. J., and Wang, L.-H. (1995) J. Biol. Chem. 270, 24019-24023
5. Smith, W. L., Garavito, R. M., and DeWitt, D. L. (1996) J. Biol. Chem. 271, 33157-33160
6. Morita, I., Schindler, M., Regier, M. K., Otto, J. C., Hori, T., DeWitt, D. L., and Smith, W. L. (1995) J. Biol. Chem. 270, 10902-10908
7. Tanaka, Y., Ward, S., and Smith, W. L. (1987) J. Biol. Chem. 262, 1374-1381
8. Watanabe, K., Kurihara, K., and Hayaishi, O. (1997) Biochem. Biophys. Res. Commun. 235, 148-152
9. Ogorochi, T., Ujihara, M., and Narumiya, S. (1987) J. Neurochem. 48, 900-909
10. Watanabe, K., Kurihara, K., and Suzuki, T. (1999) Biochim. Biophys. Acta 1439, 406-414
11. Naraba, H., Murakami, M., Matsumoto, H., Shimbara, S., Ueno, A., Kudo, I., and Oh-ishi, S. (1998) J. Immunol. 160, 2974-2982
12. Fournier, T., Fadok, V., and Henson, P. M. (1997) J. Biol. Chem. 272, 31065-31072
13. Jakobsson, P.-J., Thoren, S., Morgenstern, R., and Samuelsson, B. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7220-7225
14. Jakobsson, P.-J., Morgenstern, R., Mancini, J., Ford-Hunchinton, A., and Persson, B. (1999) Protein Sci. 8, 689-692
15. Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh-ishi, S., and Kudo, I. (2000) J. Biol. Chem. 275, 32783-32792
16. Murakami, M., Matsumoto, R., Austen, K. F., and Arm, J. P. (1994) J. Biol. Chem. 269, 22269-22275
17. Nakatani, Y., Tanioka, Y., Sunaga, S., Murakami, M., and Kudo, I. (2000) J. Biol. Chem. 275, 1161-1168
18. Johnson, J. L., Beito, T. G., Krco, C. J., and Toft, D. O. (1994) Mol. Cell. Biol. 14, 1956-1963
19. Murakami, M., Nakatani, Y., and Kudo, I. (1996) J. Biol. Chem. 271, 30041-30051
20. Salinas, A. E., and Wong, M. G. (1999) Curr. Med. Chem. 6, 279-309
21. Hutchinson, K. A., Stancato, L. F., Qwens-Grillo, J. K., Johnson, J. L., Krishna, P., Toft, D. O., and Pratt, W. B. (1995) J. Biol. Chem. 270, 18841-18847
22. Kanaoka, Y., Ago, H., Inagaki, E., Nanayama, T., Miyano, M., Kikuno, R., Fujii, Y., Eguchi, N., Toh, H., Urade, Y., and Hayaishi, O. (1997) Cell 90, 1085-1095
23. Kuwata, H., Nakatani, Y., Murakami, M., and Kudo, I. (1998) J. Biol. Chem. 273, 1733-1740
24. Sullivan, W., Stensgard, B., Caucutt, G., Bartha, B., McMahon, N., Alnemri, E. S., Litwack, G, and Toft, D. (1997) J. Biol. Chem. 272, 8007-8012
25. Dittmar, K. D., Demady, D. R., Stancato, L. F., Krishna, P., and Pratt, W. B. (1997) J. Biol. Chem. 272, 21213-21220
26. Morishima, Y., Kanelakis, K. C., Silverstein, A. M., Dittmar, K. D., Estrada, L., and Pratt, W. B. (2000) J. Biol. Chem. 275, 6894-6900
27. Bohenm, S. P. (1998) Mol. Cell. Biol. 18, 3330-3339
28. Freeman, B. C., Felts, S. J., Toft, D. O., and Yamamoto, K. R. (2000) Genes Dev. 14, 422-434
29. Holt, S. E., Aisner, D. L., Baur, J., Tesmer, V. M., Dy, M., Ouellette, M., Trager, J. B., Morin, G. B., Toft, D. O., Shay, J. W., Wright, W. E., and White, M. A. (1999) Genes Dev. 13, 817-826
30. Weaver, A. J., Sullivan, W. P., Felts, S. J., Owen, B. A., and Toft, D. O. (2000) J. Biol. Chem. 275, 23045-23052
31. Nagata, A., Suzuki, Y., Igarashi, M., Eguchi, N., Toh, H., Urade, Y., and Hayaishi, O. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4020-4024
32. Beuckmann, C. T., Aoyagi, M., Okazaki, I., Hiroike, T., Toh, H., Hayaishi, O., and Urade, Y. (1999) Biochemistry 38, 8006-8013
33. Tanaka, T., Urade, Y., Kimura, H., Eguchi, N., Nishikawa, A., and Hayaishi, O. (1997) J. Biol. Chem. 272, 15789-15795
34. Watanabe, K., Yoshida, R., Shimizu, T., and Hayaishi, O. (1985) J. Biol. Chem. 260, 7035-7041
35. Suzuki, T., Fujii, Y., Miyano, M., Chen, L. Y., Takahashi, T., and Watanabe, K. (1999) J. Biol. Chem. 274, 241-248
36. Pinzar, E., Miyako, M., Kanaoka, Y., Urade, Y., and Hayaishi, O. (2000) J. Biol. Chem. 275, in press
37. Spencer, A. G., Woods, J. W., Arakawa, T., Singer, I. I., and Smith, W. L. (1998) J. Biol. Chem. 273, 9886-9893
38. Murakami, M., Kambe, T., Shimbara, S., Yamamoto, S., Kuwata, H., and Kudo, I. (1999) J. Biol. Chem. 274, 29927-29936
39. Morita, I., Schindler, M., Reiger, M. K., Otto, J. C., Hori, T., DeWitt, D. L., and Smith, W. L. (1995) J. Biol. Chem. 270, 10902-10908
40. Liou, J.-Y., Shyue, S.-K., Tsai, M.-J., Chung, C.-L., Chu, K.-Y., and Wu, K. K. (2000) J. Biol. Chem. 275, 15314-15320
41. Spencer, A. G., Woods, J. W., Arakawa, T., Singler, I. I., and Smith, W. L. (1998) J. Biol. Chem. 273, 9886-9893
42. Dixon, R. A., Diehl, R. E., Opas, E., Rands, E., Vickers, P. J., Evans, J. F., Gillard, J. W., and Miller, D. K. (1990) Nature 343, 282-284
43. Harada, Y., Hatanaka, K., Kawamura, M., Saito, M., Ogino, M., Majima, M., Ohno, T., Ogino, K., Yamamoto, K., Taketani, Y., Yamamoto, S., and Katori, M. (1996) Prostaglandins 51, 19-33


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Hammarberg, M. Hamberg, A. Wetterholm, H. Hansson, B. Samuelsson, and J. Z. Haeggstrom
Mutation of a Critical Arginine in Microsomal Prostaglandin E Synthase-1 Shifts the Isomerase Activity to a Reductase Activity That Converts Prostaglandin H2 into Prostaglandin F2{alpha}
J. Biol. Chem., January 2, 2009; 284(1): 301 - 305.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
V. Jadhav, A. Jabre, M.-F. Chen, and T. J.-F. Lee
Presynaptic Prostaglandin E2 EP1-Receptor Facilitation of Cerebral Nitrergic Neurogenic Vasodilation
Stroke, January 1, 2009; 40(1): 261 - 269.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. N. Somayaji, S. Ritchie, M. Sahraei, I. Marriott, and M. C. Hudson
Staphylococcus aureus Induces Expression of Receptor Activator of NF-{kappa}B Ligand and Prostaglandin E2 in Infected Murine Osteoblasts
Infect. Immun., November 1, 2008; 76(11): 5120 - 5126.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M Korotkova, S B. Helmers, I Loell, H Alexanderson, C Grundtman, C Dorph, I E Lundberg, and P-J Jakobsson
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis
Ann Rheum Dis, November 1, 2008; 67(11): 1596 - 1602.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J Monfort, J-P Pelletier, N Garcia-Giralt, and J Martel-Pelletier
Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues
Ann Rheum Dis, June 1, 2008; 67(6): 735